{
    "name": "amphotericin B deoxycholate",
    "comment": "Rx",
    "other_names": [
        "amphotericin B (conventional)"
    ],
    "classes": [
        "Antifungals",
        "Systemic"
    ],
    "source": "https://reference.medscape.com/drug/amphotericin-b-conventional-amphotericin-b-deoxycholate-342582",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B",
            "Lactation: Excretion in milk is unknown; due to the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue nursing or whether to discontinue the drug, taking into account the importance of the drug to the mother"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in milk is unknown; due to the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue nursing or whether to discontinue the drug, taking into account the importance of the drug to the mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts",
                "Should not be given in doses greater than 1.5 mg/kg",
                "Exercise caution to prevent inadvertent overdosage, which may result in potentially fatal cardiac or cardiopulmonary arrest",
                "Verify the product name and dosage pre-administration, especially if dose exceeds 1.5 mg/kg"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Therapy should be administered intravenously under close clinical observation by medically trained personnel; should be reserved for treatment of patients with progressive, potentially life-threatening fungal infections due to susceptible organisms",
                "Indicated for patients with progressive and potentially fatal fungal infections",
                "Do not use for noninvasive fungal infections (eg, oral thrush, vaginal candidiasis, esophageal candidiasis) in patients with normal neutrophil counts",
                "Acute reactions including fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, and tachypnea are common 1 to 3 hours after starting an intravenous infusion; reactions are usually more severe with first few doses of amphotericin B and usually diminish with subsequent doses",
                "Rapid intravenous infusion has been associated with hypotension, hypokalemia, arrhythmias, and shock and should, therefore, be avoided",
                "Since acute pulmonary reactions have been reported in patients given therapy during or shortly after leukocyte transfusions, it is advisable to temporarily separate these infusions as far as possible and to monitor pulmonary function",
                "Caution when coadministration with other drugs that cause hypokalemia (eg, corticosteroids, digoxin)",
                "Cases of new-onset dilated cardiomyopathy with subsequent heart failure have been reported; symptoms normalized within 6 months of discontinuation",
                "Leukoencephalopathy has been reported following use of amphotericin B; literature reports have suggested that total body irradiation may be a predisposition",
                "Amphotericin B should be used with care in patients with reduced renal function; frequent monitoring of renal function is recommended; in some patients hydration and sodium repletion prior to administration may reduce risk of developing nephrotoxicity; supplemental alkali medication may decrease renal tubular acidosis complications; however, do not withhold if risk of infection outweighs renal risk",
                "Whenever medication is interrupted for a period longer than seven days, therapy should be resumed by starting with the lowest dosage level, eg, 0.25 mg/kg of body weight, and increased gradually"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin and amphotericin B deoxycholate both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cidofovir",
            "description": {
                "common": "amphotericin B deoxycholate and cidofovir both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "contrast media (iodinated)",
            "description": {
                "common": "amphotericin B deoxycholate and contrast media (iodinated) both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "amphotericin B deoxycholate and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ioversol",
            "description": {
                "common": "amphotericin B deoxycholate and ioversol both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "amphotericin B deoxycholate and neomycin PO both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "streptozocin",
            "description": {
                "common": "amphotericin B deoxycholate and streptozocin both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "amphotericin B deoxycholate and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "teicoplanin",
            "description": {
                "common": "amphotericin B deoxycholate and teicoplanin both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acyclovir",
            "description": {
                "common": "acyclovir and amphotericin B deoxycholate both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atracurium",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capreomycin",
            "description": {
                "common": "amphotericin B deoxycholate and capreomycin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carboplatin",
            "description": {
                "common": "amphotericin B deoxycholate and carboplatin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cephaloridine",
            "description": {
                "common": "amphotericin B deoxycholate and cephaloridine both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisplatin",
            "description": {
                "common": "amphotericin B deoxycholate and cisplatin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colistin",
            "description": {
                "common": "amphotericin B deoxycholate and colistin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "corticotropin",
            "description": {
                "common": "amphotericin B deoxycholate, corticotropin. Mechanism: unspecified interaction mechanism. Avoid or Use Alternate Drug. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "digoxin",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of digoxin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Digoxin effects increased if hypokalemia results from Ampho B Tx."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gentamicin",
            "description": {
                "common": "amphotericin B deoxycholate and gentamicin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "amphotericin B deoxycholate and oxaliplatin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pancuronium",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "amphotericin B deoxycholate and polymyxin B both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rimabotulinumtoxinB",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of rimabotulinumtoxinB by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rocuronium",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Saccharomyces boulardii",
            "description": {
                "common": "amphotericin B deoxycholate decreases effects of Saccharomyces boulardii by unspecified interaction mechanism. Avoid or Use Alternate Drug. Systemic or oral antifungals may decrease activity of probiotic."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tobramycin",
            "description": {
                "common": "amphotericin B deoxycholate and tobramycin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vecuronium",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adefovir",
            "description": {
                "common": "adefovir and amphotericin B deoxycholate both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beclomethasone, inhaled",
            "description": {
                "common": "beclomethasone, inhaled increases toxicity of amphotericin B deoxycholate by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Corticosteroids may increase the hypokalemic effect of amphotericin B."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "amphotericin B deoxycholate, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "amphotericin B deoxycholate, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "amphotericin B deoxycholate and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and amphotericin B deoxycholate both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "amphotericin B deoxycholate and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "foscarnet",
            "description": {
                "common": "amphotericin B deoxycholate and foscarnet both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide increases toxicity of amphotericin B deoxycholate by unknown mechanism. Use Caution/Monitor. Monitor for possible increases in renal toxicity, bronchospasm, and hypotension if amphotericin is given concomitantly with ifosfamide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine increases toxicity of amphotericin B deoxycholate by unknown mechanism. Use Caution/Monitor. Monitor for possible increases in renal toxicity, bronchospasm, and hypotension if amphotericin is given concomitantly with lomustine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine increases toxicity of amphotericin B deoxycholate by unknown mechanism. Use Caution/Monitor. Monitor for possible increases in renal toxicity, bronchospasm, and hypotension if amphotericin is given concomitantly with mechlorethamine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan increases toxicity of amphotericin B deoxycholate by unknown mechanism. Use Caution/Monitor. Monitor for possible increases in renal toxicity, bronchospasm, and hypotension if amphotericin is given concomitantly with melphalan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methoxyflurane",
            "description": {
                "common": "amphotericin B deoxycholate and methoxyflurane both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mometasone inhaled",
            "description": {
                "common": "mometasone inhaled increases toxicity of amphotericin B deoxycholate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may enhance the hypokalemic effect of amphtericin B. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin increases toxicity of amphotericin B deoxycholate by unknown mechanism. Use Caution/Monitor. Monitor for possible increases in renal toxicity, bronchospasm, and hypotension if amphotericin is given concomitantly with oxaliplatin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paromomycin",
            "description": {
                "common": "amphotericin B deoxycholate and paromomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "amphotericin B deoxycholate and pentamidine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peramivir",
            "description": {
                "common": "amphotericin B deoxycholate increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab",
            "description": {
                "common": "amphotericin B deoxycholate and rituximab both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Caution should be exercised when concurrent therapy is used. Patients should be monitored for signs of renal failure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "amphotericin B deoxycholate and rituximab-hyaluronidase both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Caution should be exercised when concurrent therapy is used. Patients should be monitored for signs of renal failure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of amphotericin B deoxycholate by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of amphotericin B deoxycholate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of amphotericin B deoxycholate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "amphotericin B deoxycholate and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "amphotericin B deoxycholate and streptomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "amphotericin B deoxycholate and tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Combination may also increase tenofovir levels.  "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and amphotericin B deoxycholate both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension and amphotericin B deoxycholate both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab, amphotericin B deoxycholate. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vancomycin",
            "description": {
                "common": "amphotericin B deoxycholate and vancomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, amphotericin B deoxycholate.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xipamide",
            "description": {
                "common": "xipamide, amphotericin B deoxycholate. pharmacodynamic synergism. Use Caution/Monitor. Risk of hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "amphotericin B deoxycholate, budesonide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "amphotericin B deoxycholate, cortisone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cosyntropin",
            "description": {
                "common": "amphotericin B deoxycholate, cosyntropin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "amphotericin B deoxycholate, deflazacort. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "amphotericin B deoxycholate, dexamethasone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flucytosine",
            "description": {
                "common": "flucytosine increases effects of amphotericin B deoxycholate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "amphotericin B deoxycholate, fludrocortisone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "ganciclovir increases toxicity of amphotericin B deoxycholate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "amphotericin B deoxycholate, hydrocortisone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium chloride",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of magnesium chloride by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of magnesium citrate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of magnesium sulfate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mestranol",
            "description": {
                "common": "amphotericin B deoxycholate decreases effects of mestranol by increasing metabolism. Minor/Significance Unknown. May also cause menstrual irregularities."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "amphotericin B deoxycholate, methylprednisolone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of potassium acid phosphate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of potassium chloride by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "amphotericin B deoxycholate decreases levels of potassium citrate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "amphotericin B deoxycholate, prednisolone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "amphotericin B deoxycholate, prednisone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valganciclovir",
            "description": {
                "common": "valganciclovir increases toxicity of amphotericin B deoxycholate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zidovudine",
            "description": {
                "common": "zidovudine increases toxicity of amphotericin B deoxycholate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Hypomagnesemia",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "generalized",
            "percent": null
        },
        {
            "name": "Pain at injection site",
            "percent": null
        },
        {
            "name": "Renal function abnormalities",
            "percent": null
        },
        {
            "name": "Tachypnea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Arachnoiditis",
            "percent": null
        },
        {
            "name": "Delerium",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Leukocytosis",
            "percent": null
        },
        {
            "name": "Lumbar nerve pain",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Urinary retention",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Anuria",
            "percent": null
        },
        {
            "name": "Bone marrow suppression",
            "percent": null
        },
        {
            "name": "Cardiac arrest",
            "percent": null
        },
        {
            "name": "Coagulation defects",
            "percent": null
        },
        {
            "name": "Convulsions",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Hearing loss",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Maculopapular rash",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Vision changes",
            "percent": null
        }
    ]
}